ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Limited submitted its 31st Annual Report for FY 2025-26 and notice of the 31st Annual General Meeting scheduled for 30th September 2026.
Concord Drugs approved the notice for its 31st AGM on September 30, 2026. The board also finalized director re-appointments and set book closure dates.
Concord Drugs Ltd reported revenue from operations of ₹20.9 Cr (+53.7% YoY) and net profit of ₹1.1 Cr (+1000.0% YoY) for Q1 FY27.
Concord Drugs Ltd reported revenue from operations of ₹37.9 Cr (+264.4% YoY) and net profit of ₹0.5 Cr for Q4 FY26.